Pharmacogenetics and pharmacogenomics: A bridge to individualized cancer therapy

Pharmacogenomics

Volumn 14, Issue 3, 2013, Pages 315-324

  Weng, Liming ^a   Zhang, Li ^b   Peng, Yan ^c   Huang, R Stephanie ^a  

^a UNIVERSITY OF CHICAGO   (United States)

^b CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

^c RENMIN HOSPITAL OF WUHAN UNIVERSITY   (China)

Author keywords

anticancer agents; drug label; pharmacogenetics; pharmacogenomics

Indexed keywords

ANAPLASTIC LYMPHOMA KINASE; ANTINEOPLASTIC AGENT; BUSULFAN; CAPECITABINE; CETUXIMAB; CISPLATIN; CRIZOTINIB; DASATINIB; DENILEUKIN DIFTITOX; DIHYDROPYRIMIDINE DEHYDROGENASE; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ERLOTINIB; ESTROGEN RECEPTOR; EVEROLIMUS; EXEMESTANE; FLUOROURACIL; GEFITINIB; GLUCURONOSYLTRANSFERASE 1A1; IMATINIB; INTERLEUKIN 2 RECEPTOR ALPHA; IRINOTECAN; K RAS PROTEIN; LAPATINIB; MERCAPTOPURINE; PANITUMUMAB; PROGESTERONE RECEPTOR; STEM CELL FACTOR RECEPTOR; THIOPURINE METHYLTRANSFERASE; UNINDEXED DRUG;

BREAST CANCER; CHROMOSOME TRANSLOCATION; COLON CANCER; DRUG CYTOTOXICITY; DRUG EFFICACY; DRUG INFORMATION; DRUG RESEARCH; DRUG RESPONSE; DRUG TARGETING; EVIDENCE BASED MEDICINE; FLUORESCENCE IN SITU HYBRIDIZATION; FOOD AND DRUG ADMINISTRATION; GENE MUTATION; GENE OVEREXPRESSION; GENETIC ANALYSIS; GENETIC VARIABILITY; GERM LINE; HEAD AND NECK CANCER; HERITABILITY; HUMAN; IMMUNOHISTOCHEMISTRY; LEUKEMIA; LUNG NON SMALL CELL CANCER; LYMPHOMA; MALIGNANT NEOPLASTIC DISEASE; NEUTROPENIA; PERSONALIZED MEDICINE; PHARMACOGENETICS; PHARMACOGENOMICS; PHILADELPHIA 1 CHROMOSOME; POLYMERASE CHAIN REACTION; REVIEW; SINGLE NUCLEOTIDE POLYMORPHISM; UNITED STATES; UNSPECIFIED SIDE EFFECT;

6-MERCAPTOPURINE; ANTINEOPLASTIC AGENTS; DEOXYCYTIDINE; DRUG DISCOVERY; FLUOROURACIL; GENETIC VARIATION; HUMANS; INDIVIDUALIZED MEDICINE; METHYLTRANSFERASES; NEOPLASMS; PHARMACOGENETICS; POLYMORPHISM, SINGLE NUCLEOTIDE;

EID: 84873656874     PISSN: 14622416     EISSN: 17448042     Source Type: Journal    
DOI: 10.2217/pgs.12.213     Document Type: Review

References (45)

1. Schimke RN. Drugs and heredity. Pharmacogenetics - the study of heritable variations in drug response. J. Kans. Med. Soc. 70(3), 146-150 (1969).
2. Roses AD. Pharmacogenetics and the practice of medicine. Nature 405(6788), 857-865 (2000).
3. Wang L. Pharmacogenomics: a systems approach. Wiley Interdiscip. Rev. Syst. Biol. Med. 2(1), 3-22 (2010).
4. Thomas F, Thomas C. The anticancer drug development pipeline of the pharmaceutical (P) and biotech (B) industries. J. Clin. Oncol. 27(Suppl.), Abstract e14589 (2009).
5. Visscher PM, Hill WG, Wray NR. Heritability in the genomics era - concepts and misconceptions. Nat. Rev. Genet. 9(4), 255-266 (2008).
6. Yang A, Palmer AA, De Wit H. Genetics of caffeine consumption and responses to caffeine. Psychopharmacology 211(3), 245-257 (2010).
7. Faraday N, Yanek LR, Mathias R et al. Heritability of platelet responsiveness to aspirin in activation pathways directly and indirectly related to cyclooxygenase-1. Circulation 115(19), 2490-2496 (2007).
8. Dolan ME, Newbold KG, Nagasubramanian R et al. Heritability and linkage analysis of sensitivity to cisplatin-induced cytotoxicity. Cancer Res. 64(12), 4353-4356 (2004).
9. Watters JW, Kraja A, Meucci MA, Province MA, Mc Leod HL. Genome-wide discovery of loci influencing chemotherapy cytotoxicity. Proc. Natl Acad. Sci. USA 101(32), 11809-11814 (2004).
10. Peters EJ, Motsinger-Reif A, Havener TM et al. Pharmacogenomic characterization of US FDA-approved cytotoxic drugs. Pharmacogenomics 12(10), 1407-1415 (2011).
11. Huang RS, Ratain MJ. Pharmacogenetics and pharmacogenomics of anticancer agents. CA Cancer J. Clin. 59(1), 42-55 (2009).
12. Liang P, Pardee AB. Analysing differential gene expression in cancer. Nat. Rev. Cancer. 3(11), 869-876 (2003).
13. Kim S, Misra A. SNP genotyping: technologies and biomedical applications. Annu. Rev. Biomed. Eng. 9, 289-320 (2007).
14. Syvanen AC. Accessing genetic variation: genotyping single nucleotide polymorphisms. Nat. Rev. Genet. 2(12), 930-942 (2001).
15. Hall N. Advanced sequencing technologies and their wider impact in microbiology. J. Exp. Biol. 210(Pt 9), 1518-1525 (2007).
16. Huang RS, Dolan ME. Approaches to the discovery of pharmacogenomic markers in oncology: 2000-2010-2020. Pharmacogenomics 11(4), 471-474 (2010).
17. Lennard L, Lilleyman JS, van Loon J, Weinshilboum RM. Genetic variation in response to 6-mercaptopurine for childhood acute lymphoblastic leukaemia. Lancet 336(8709), 225-229 (1990).
18. Morel A, Boisdron-Celle M, Fey L et al. Clinical relevance of different dihydropyrimidine dehydrogenase gene single nucleotide polymorphisms on 5-fluorouracil olerance. Mol. Cancer Ther. 5(11), 2895-2904 (2006).
19. Hsu DS, Balakumaran BS, Acharya CR et al. Pharmacogenomic strategies provide a rational approach to the treatment of cisplatin-resistant patients with advanced cancer. J. Clin. Oncol. 25(28), 4350-4357 (2007).
20. Van Den Akker-van Marle ME, Gurwitz D, Detmar SB et al. Cost-effectiveness of pharmacogenomics in clinical practice: a case study of thiopurine methyltransferase genotyping in acute lymphoblastic leukemia in Europe. Pharmacogenomics 7(5), 783-792 (2006).
21. Wong WB, Carlson JJ, Thariani R, Veenstra DL. Cost effectiveness of pharmacogenomics: a critical and systematic review. Pharmacoeconomics 28(11), 1001-1013 (2010).
22. Lindpaintner K. Pharmacogenetics and pharmacogenomics in drug discovery and development: an overview. Clin. Chem. Lab. Med. 41(4), 398-410 (2003).
23. Wang L, Weinshilboum RM. Pharmacogenomics: candidate gene identification, functional validation and mechanisms. Hum. Mol. Genet. 17(R2), R174-R179 (2008).
24. Deverka PA, Vernon J, Mc Leod HL. Economic opportunities and challenges for pharmacogenomics. Annu. Rev. Pharmacol. Toxicol. 50, 423-437 (2010).
25. Yates CR, Krynetski EY, Loennechen T et al. Molecular diagnosis of thiopurine S-methyltransferase deficiency: genetic basis for azathioprine and mercaptopurine intolerance. Ann. Intern. Med. 126(8), 608-614 (1997).
26. Stanulla M, Schaeffeler E, Flohr T et al. Thiopurine methyltransferase (TPMT) genotype and early treatment response to mercaptopurine in childhood acute lymphoblastic leukemia. JAMA 293(12), 1485-1489 (2005).
27. Mc Leod HL, Siva C. The thiopurine S-methyltransferase gene locus - implications for clinical pharmacogenomics. Pharmacogenomics 3(1), 89-98 (2002).
28. Petros WP, Evans WE. Pharmacogenomics in cancer therapy: is host genome variability important? Trends Pharmacol. Sci. 25(9), 457-464 (2004).
29. Becquemont L, Alfirevic A, Amstutz U et al. Practical recommendations for pharmacogenomics-based prescription: 2010 ESF-UB Conference on Pharmacogenetics and Pharmacogenomics. Pharmacogenomics 12(1), 113-124 (2011).
30. Lu ZH, Zhang R, Diasio RB. Purification and characterization of dihydropyrimidine dehydrogenase from human liver. J. Biol. Chem. 267(24), 17102-17109 (1992).
31. Wei X, Mc Leod HL, Mc Murrough J, Gonzalez FJ, Fernandez-Salguero P. Molecular basis of the human dihydropyrimidine dehydrogenase deficiency and 5-fluorouracil toxicity. J. Clin. Invest. 98(3), 610-615 (1996).
32. Magne N, Etienne-Grimaldi MC, Cals L et al. Dihydropyrimidine dehydrogenase activity and the IVS14+1G>A mutation in patients developing 5FU-related toxicity. Br. J. Clin. Pharmacol. 64(2), 237-240 (2007).
33. Amstutz U, Froehlich TK, Largiader CR. Dihydropyrimidine dehydrogenase gene as a major predictor of severe 5-fluorouracil toxicity. Pharmacogenomics 12(9), 1321-1336 (2011).
34. van Kuilenburg AB, Meijer J, Mul AN et al. Intragenic deletions and a deep intronic mutation affecting pre-m RNA splicing in the dihydropyrimidine dehydrogenase gene as novel mechanisms causing 5-fluorouracil toxicity. Hum. Genet. 128(5), 529-538 (2010).
35. Amstutz U, Farese S, Aebi S, Largiader CR. Dihydropyrimidine dehydrogenase gene variation and severe 5-fluorouracil toxicity: a haplotype assessment. Pharmacogenomics 10(6), 931-944 (2009).
36. Schwab M, Zanger UM, Marx C et al. Role of genetic and nongenetic factors for fluorouracil treatment-related severe toxicity: a prospective clinical trial by the German 5-FU Toxicity Study Group. J. Clin. Oncol. 26(13), 2131-2138 (2008).
37. Lievre A, Bachet JB, Le Corre D et al. KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer. Cancer Res. 66(8), 3992-3995 (2006).
38. Karapetis CS, Khambata-Ford S, Jonker DJ et al. K-ras mutations and benefit from cetuximab in advanced colorectal cancer. N. Engl. J. Med. 359(17), 1757-1765 (2008).
39. Kranenburg O. The KRAS oncogene: past, present, and future. Biochim. Biophys. Acta 1756(2), 81-82 (2005).
40. Amado RG, Wolf M, Peeters M et al. Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J. Clin. Oncol. 26(10), 1626-1634 (2008).
41. Soda M, Choi YL, Enomoto M et al. Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature 448(7153), 561-566 (2007).
42. Zhang S, Wang F, Keats J et al. Crizotinib-resistant mutants of EML4-ALK identified through an accelerated mutagenesis screen. Chem. Biol. Drug Des. 78(6), 999-1005 (2011).
43. Doebele RC, Pilling AB, Aisner DL et al. Mechanisms of resistance to crizotinib in patients with ALK gene rearranged non-small cell lung cancer. Clin. Cancer Res. 18(5), 1472-1482 (2012).
44. Longo DL. Tumor heterogeneity and personalized medicine. N. Engl. J. Med. 366(10), 956-957 (2012).
45. Cancer Genome Atlas Network. Comprehensive molecular portraits of human breast tumours. Nature 490(7418), 61-70 (2012).